International Immunology, Vol 10, 1907-1916, Copyright © 1998 by Oxford University Press
B Agrawal, MJ Krantz, MA Reddish and BM Longenecker
Antigen-specific MHC class II- and class I-restricted helper and cytotoxic
T cell responses are important anti-cancer immune responses. MUC1 mucin is
a potentially important target for immunotherapy because of its high
expression on most human adenocarcinomas. MUC1 peptide- specific type 1 T
cell responses were generated in vitro using human peripheral blood
lymphocytes (PBL), incubated with liposomes containing synthetic MUC1
lipopeptide antigen. Only two weekly stimulations with the liposomal MUC1
formulation led to the generation of potent anti- MUC1-specific T cell
proliferation as well as class I-restricted cytotoxic responses. Thus the
use of PBL pulsed with liposome- encapsulated antigen provides an effective
approach of rapidly generating effective antigen-presenting cell (APC)
function as well as antigen specific T cells in vitro. It may be feasible
to use this technology for the rapid and effective generation of APC and/or
T cells as cellular vaccines for adenocarcinomas.
ARTICLES
Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes
Biomira Inc., Edmonton, Alberta, Canada.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Gridelli, A. Rossi, P. Maione, M. L. Ferrara, V. Castaldo, and P. C. Sacco Vaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy Oncologist, September 1, 2009; 14(9): 909 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sangha and C. Butts L-BLP25: A Peptide Vaccine Strategy in Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4652s - 4654s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Rubinstein, M. Karmely, R. Ziv, I. Benhar, O. Leitner, S. Baron, B.-Z. Katz, and D. H. Wreschner MUC1/X Protein Immunization Enhances cDNA Immunization in Generating Anti-MUC1 {alpha}/{beta} Junction Antibodies that Target Malignant Cells Cancer Res., December 1, 2006; 66(23): 11247 - 11253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. U. Vogel, B. E. Beer, J. zur Megede, H.-G. Ihlenfeldt, G. Jung, S. Holzammer, D. I. Watkins, J. D. Altman, R. Kurth, and S. Norley Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge J. Gen. Virol., January 1, 2002; 83(1): 81 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Brossart, K. S. Heinrich, G. Stuhler, L. Behnke, V. L. Reichardt, S. Stevanovic, A. Muhm, H.-G. Rammensee, L. Kanz, and W. Brugger Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies Blood, June 15, 1999; 93(12): 4309 - 4317. [Abstract] [Full Text] [PDF]
|
|